… More comprehensive reviews of the epidemiology and associated burden of heart failure
have been published by McMurray and colleagues1 and more recently by Cowie and …

Clinically overt heart failure is common, costly, disabling, and deadly; it remains so despite
the tremendous benefit of angiotensin-converting enzyme inhibitors. Better treatments for and …

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is
projected to worsen. To date, there are no approved therapies available for reducing mortality …

Background Trials of statin therapy have had conflicting findings on the risk of development
of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of …

Background Approximately 50% of patients with heart failure have a left ventricular ejection
fraction of at least 45%, but no therapies have been shown to improve the outcome of these …

BACKGROUND Endothelins are recently characterized vasoconstrictor peptides. As chronic
heart failure (CHF) is characterized by peripheral arteriolar and renal vasoconstriction, we …

Background Although inhibitors of the renin–angiotensin–aldosterone system can slow the
progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (…

Background— Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral
endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition …

… McMurray JJ,… Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow
GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA …

Guidelines on heart failure (HF) stress the importance of lifestyle advice, although there is
little evidence that such recommendations improve symptoms or prognosis. Patients …